A new genetic 'barcode' for malaria parasites has been found which could be used to track and contain the spread of the disease, according to new research led by the London School of Hygiene & Tropical Medicine. Malaria kills around 600,000 people per year, and increased population mobility through international air travel carries further risks of re-introducing parasites to elimination areas and dispersing drug-resistant parasites to new regions. A simple genetic marker that quickly and accurately identifies the geographic origin of infections would be a valuable tool for locating the source of outbreaks, and spotting the spread of drug-resistant parasites from Asia to Africa. New research published in Nature Communications has found a highly predictive barcode in the genetic sequence of the malaria parasite Plasmodium falciparum which can be used to identify the geographic origin of a parasite from a blood sample and monitor its spread. The researchers from the London School of Hygiene & Tropical Medicine analysed the DNA of over 700 P. falciparum malaria parasites taken from patients in 14 countries in West Africa, East Africa, South East Asia, Oceania and South America. They found several short genetic sequences which were distinct in the DNA of parasites from … Continue reading →

Irvine, CA and Annapolis Junction, MD (PRWEB) June 16, 2014 Proove Biosciences, a commercial and research leader in personalized medicine, presented the PILL 2 study at last weeks I nternational Conference on Opioids. The conference was presented by the Journal of Opioid Management and hosted by Harvard Medical School. The PILL 2 study examined the prevalence of genetic variations in a population of chronic pain patients who were taking prescription opioids. Proove researchers found that there is in fact a greater prevalence of these genetic variations in the study group vs. the control population. We believe the PILL 2 study shows how genetics can play an important role in personalizing treatment for chronic pain, stated Brian Meshkin, President of Proove Biosciences. When physicians are armed with knowledge about their patients genetic profile, they are better able to assess how that patient will respond to certain medications and treatments. This study was only a baseline metric providing a benchmark to direct our future research efforts. We are analyzing co-occurring disorders, evaluating additional SNPs, haplotypes and continuously developing new IRB approved prospective studies. The International Conference on Opioids explores emerging opioid research and initiatives aimed at improving patient care and reducing harm. … Continue reading →

Obesity Weight (Stem Cell Therapy) The subject matter of this video Obesity Weight. By: Mohammad Sadique … Continue reading →

ReNeuron Group Quote more Price: 2.90 Chg: 0.12 Chg %: 3.97% Date: 16:52 Stem cell treatment developer ReNeuron lost an increased 7.1m in a "transformational" year to end-March but still had plenty of cash in the bank as it moves into new cell manufacturing facility and files an investigational new drug (IND) application in the US early next year. The AIM-listed company held cash outflow from operating activities roughly flat at 6m over the period, leaving cash, cash equivalents and bank deposits at period end of 20.92m, thanks to the 23.44m net fundraising in August 2013. Chairman Bryan Morton said it was a transformational year for the business, both operationally and financially, as its lead stem cell therapy candidate for stroke entered Phase II clinical trials and the company began clinical development of a candidate for critical limb ischaemia. He also noted that in both cases, and earlier-than-planned, ReNeuron gained regulatory approval to use a cryopreserved variant of its lead 'CTX' stem cell product line, which gives the treatments the potential to have "significant commercial and competitive advantages". He confirmed the move to new cell manufacturing facility in South Wales early next year was on track, "which we believe will … Continue reading →

Nanomatriaux 2014 - AGuIX in nanomedicine Nanomatriaux 2014 - AGuIX in nanomedicine Vido 03/18 Quels enjeux et perspectives pour les NANOMATERIAUX ? 4me dition des Journe industrielles Nanomatr... By: CarnotMINES … Continue reading →